These differences matter clinically: larger average weight loss translates into bigger improvements in blood pressure, glycemic measures, sleep apnea metrics, mobility, and quality of life for many patients
Although many treatments effective in animal models of IRI have failed to translate into clinical use, glucagon-like peptide 1 (GLP-1) and the GLP-1 receptor (GLP-1R) agonist exenatide have shown benefits in IRI in both animal models (47) and small early-phase clinical trials (8, 9)
combined with the impact of gastrointestinal reactions on the absorption and adherence of oral contraceptives, the risk is further amplified, particularly during the initiation or dose-escalation phases of tirzepatide (161, 162, 169)
Current guidelines for the treatment of diabetes and obesity recommend a step-wise approach starting with lifestyle interventions aimed at body weight loss, an increase in physical activity, and additional measures for healthier choices in everyday decisions and habits